News Release: Precision BioLogic Launches Product to Improve Inhibitor Testing for People with Hemophilia A
HALIFAX, February 11, 2019—Precision BioLogic Inc., a leading developer of hemostasis diagnostic products, is pleased to announce the availability of its new CRYOcheck Factor VIII Inhibitor Kit in Canada, the European Union, Australia, and New Zealand following market authorization by Health Canada and respective in-country regulatory authorities last month.
The presence of factor VIII (FVIII) inhibitors reduces therapy effectiveness and is one of the most complex and costly complications for people with hemophilia A. Because of this, it is important for clinical laboratories to have a testing system that can accurately and precisely quantify FVIII inhibitors in patient samples.
Follow link above to read full release
About Affinity Biologicals Affinity Biologicals Inc. was founded in 1987 by Hugh and Patricia Hoogendoorn. With a strong background in hemostasis research and a focus on reagent and assay development, Affinity has become a primary manufacturer of more than 300 reagents and kits used in hemostasis and thrombosis research and diagnostics. Affinity’s product line includes: an extensive line of coagulation related antibodies, conjugates, matched-pair antibody sets for immunoassay of human and animal analytes, the VisuLize™ line of complete ELISA kits, and a full line of human plasma products including VisuDep™ Immune-Depleted Factor-Deficient Plasmas, VisuCal™ Calibrator Plasma and VisuCon™ Control Plasmas. Services include protein purification, antibody production, assay development, custom manufacturing including custom lyophilization and proficiency testing materials. All products are manufactured in its Ancaster, ON (Canada) facility, products are sold direct in North America and worldwide through a network of branded and private-label distributors. For more information, visit www.affinitybiologicals.com. About Precision BioLogic Precision BioLogic Inc. is a privately-held company that develops, manufactures and markets the cryocheck™ line of frozen products used by medical professionals and researchers around the globe to diagnose coagulation disorders. Precision BioLogic also has several active initiatives with pharmaceutical partners who seek to ensure that the diagnostic implications for their novel therapeutic agents have been well characterized. For more information, visit www.precisionbiologic.com. For more information, contact: Elaine Benoit, Marketing & Communications Manager, Precision BioLogic [email protected] / 902.430.7795]]>
Working to Improve Hemophilia A Testing: Precision BioLogic presents new data at the 64th Annual SSC meeting
See original release here For Immediate Release HALIFAX, July 19, 2018—Precision BioLogic today unveiled data from a study using a new kit for a Modified Nijmegen-Bethesda Assay (MNBA) at the International Society on Thrombosis and Haemostasis’ Scientific and Standardization Committee (SSC) meeting in Dublin. Recognizing the need to standardize and improve Factor VIII (FVIII) inhibitor testing for people with hemophilia A, the company developed the new MNBA kit and the recent study in collaboration with Roche and Genentech, a member of the Roche Group. Data presented builds on findings released at the Thrombosis & Hemostasis Societies of North America (THSNA) 2018 Summit in San Diego, California and the World Federation of Hemophilia (WFH) 2018 World Congress in Glasgow, Scotland. The latest data demonstrate that a bovine-based chromogenic MNBA is suitable for FVIII inhibitor measurement in plasma samples containing HEMLIBRA® (emicizumab-kxwh), a bispecific antibody that is approved by the U.S. Food and Drug Administration (FDA) and European Commission for the prophylactic treatment of hemophilia A with factor VIII inhibitors. “We’re seeing promising advancements in the treatment of bleeding disorders,” says Paul Empey, President & CEO of Precision BioLogic. “We are hopeful that combining accurate diagnosis and monitoring with potential advancements could improve the quality of life for people with bleeding disorders. Precision BioLogic is proud to be at the forefront of this promising research.” A poster of the latest study, Emicizumab Impact on Factor VIII Inhibitor Determination in Plasma Samples from Persons with Hemophilia A (PwHA) Using a New Kit for Modified Nijmegen-Bethesda Assay (MNBA), as well as previous studies, can be downloaded from the publications page of the Precision BioLogic website. Precision BioLogic’s newly developed MNBA kit was used in the study. To eliminate FVIII depleted plasma as a potential source of variant and standardize inhibitor titer measurement, the kit was developed with the following components:
- Imidazole-buffered pooled normal plasma
- Imidazole-buffered bovine serum albumin
- Positive FVIII inhibitor control
- FVIII inhibitor-free human plasma
See original press release here Precision BioLogic Inc. Banks on Developing New Diagnostic Tools From: Atlantic Canada Opportunities Agency News release
“The Government of Canada focuses on supporting scientific research and providing equipment that Canadian researchers need to succeed in creating new technologies and medicines to diagnose diseases and treat patients. We are pleased to help an innovative company such as Precision BioLogic develop new products for identifying coagulation disorders.” – The Honourable Navdeep Bains, Minister of Innovation, Science and Economic Development and Minister responsible for ACOA “Investments such as this bring innovative services and more opportunities to our country, helping to generate wealth and economic growth in Atlantic Canada. This project will encourage Precision BioLogic Incorporated to bring additional focus to its commercialization and to reach new markets.” – Darren Fisher, Member of Parliament for Dartmouth-Cole Harbour “Precision BioLogic has been developing, manufacturing, and marketing frozen diagnostic products for more than 25 years. This funding will allow us to develop new products to help in the diagnosis of coagulation disorders.” – Paul Empey, President & CEO of Precision BioLogic Incorporated
ContactsAlex Smith Director of Communications & Outreach Atlantic Canada Opportunities Agency Phone: 902-426-9417 / 902-830-3839 (cell) Email: [email protected] Elaine Benoit Marketing & Communications Manager Phone: 902-468-6422 x 357 / 902-430-7795 (cell) Email: [email protected]
Precision BioLogic Presents New Approach to Standardize and Improve Inhibitor Testing for People with Hemophilia A
See original release New data highlights promising performance of a new kit for use in a modified Nijmegen-Bethesda Assay For Immediate Release: HALIFAX, March 13, 2018—Precision BioLogic, in collaboration with Roche and Genentech, a member of the Roche Group, unveiled data from the study of a new kit for a modified Nijmegen-Bethesda Assay (MNBA) at the Thrombosis & Hemostasis Societies of North America (THSNA) summit in San Diego, California last week. Recognizing the need to standardize and improve Factor VIII (FVIII) inhibitor testing for people with hemophilia A, the companies collaborated on the development of the new MNBA kit and the recent study. According to the study, the new kit shows promise for laboratories seeking a standardized inhibitor assay suitable for clinical management or multi-center clinical studies of people with hemophilia A. The study compared FVIII inhibitor values determined using the new MNBA kit with both a chromogenic assay and a one-stage, clot-based FVIII assay. The chromogenic assay showed superior reproducibility compared to the one-stage clotting assay. In addition, the study indicated that the MNBA kit could potentially help improve the high variability in the FVIII inhibitor assay. Based on the study results, Precision BioLogic plans to commercialize the kit and will seek clearance from regulatory authorities around the globe beginning in late 2018. The company will continue to look for other opportunities to innovate in the field of hemostasis and diagnostics. “Precision BioLogic has been developing, manufacturing and marketing hemostasis diagnostic products for more than 25 years,” says Paul Empey, President & CEO of Precision BioLogic. “We’re excited to expand our product offerings and make a meaningful contribution that has the potential to improve the quality of life for people with hemophilia.” In the study, the modifications to the MNBA included a heat treatment of plasma samples and substitution of FVIII deficient plasma with an albumin solution. To standardize inhibitor titer measurement, the kit was developed with the following components: ● Imidazole-buffered pooled normal plasma ● Imidazole-buffered bovine serum albumin to replace FVIII deficient plasma in the Nijmegen assay ● Positive FVIII inhibitor control ● FVIII inhibitor-free human plasma All kit components were frozen, similar to Precision BioLogic’s line of CRYOcheck™ diagnostic products, which closely resemble frozen patient samples. Frozen plasma samples from people with hemophilia A with a history of FVIII inhibitors and from normal donors were used in the study. A poster of the study, Performance of a New Kit for a Modified Nijmegen-Bethesda Assay: Comparison of a Chromogenic Versus a Clot-based Factor VIII Inhibitor Assay in Plasma from Persons with Hemophilia A (PwHA), can be downloaded from the Precision BioLogic website. About Hemophilia A and Inhibitors Hemophilia A is an inherited bleeding disorder caused by insufficient clotting factor VIII (FVIII) in the blood. People with hemophilia A experience prolonged bleeding, which can lead to permanent joint damage and life-threatening hemorrhages. The standard treatment for people with hemophilia A without inhibitors is intravenous (IV) FVIII replacement therapy with recombinant FVIII (rFVIII) or plasma-derived FVIII (pdFVIII) concentrates. Prophylaxis, the regular infusion of clotting factor concentrates, is used to prevent bleeds thereby minimizing joint damage. Unfortunately, up to 30% of people with hemophilia A develop inhibitors, an immune response to treatment with clotting factor concentrates. Inhibitors make it more difficult to manage and treat hemophilia. In fact, according to the World Federation of Hemophilia, apart from access to care and treatment, inhibitors are the most serious challenge in hemophilia care today.1 While routine blood tests may suggest the presence of inhibitors, specialized testing is important to confirm not only the presence of inhibitors but also the quantitation to effectively adjust treatment. Current methods for inhibitor testing vary from lab to lab and there is not an FDA-cleared gold standard for reference. About Precision BioLogic Precision BioLogic is a privately-held company that develops, manufactures and markets specialized products used by medical professionals and researchers around the globe to diagnose coagulation disorders. Precision BioLogic also has several active initiatives with pharmaceutical partners who seek to ensure that the diagnostic implications for their novel therapeutic agents have been well characterized. For more information, visit www.precisionbiologic.com. – 30 – For more information, contact: Elaine Benoit, Marketing & Communications Manager Precision BioLogic [email protected] 902.430.7795 1 World Federation of Hemophilia. Current issues in inhibitors. Available at https://www.wfh.org/en/Current-issues-in-inhibitors. Accessed on February 22, 2018.]]>